FDA Clearance Tracker · P230036-S013
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Last checked: Nov 20, 2026Latest source record: Aug 8, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Aug 8, 2025
Approved
Time to decision
29 days
Received Jul 10, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230036-S013
- Device name
- Esprit BTK Everolimus Eluting Resorbable Scaffold System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Santa Clara, CA
- Received
- Jul 10, 2025
- Decided
- Aug 8, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230036
Device type
- Device type
- Scaffold, infrapopliteal, absorbable (NXW)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
approval of revisions to the Esprit BTK-PAS New Enrollment Study protocol (ABT-CIP-10519 Ver. C)
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.